Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
16 USD | +1.91% | -0.74% | +13.31% |
Financials (USD)
Sales 2024 * | 168M | Sales 2025 * | 299M | Capitalization | 1.51B |
---|---|---|---|---|---|
Net income 2024 * | -48M | Net income 2025 * | 58M | EV / Sales 2024 * | 8.85 x |
Net cash position 2024 * | 19.66M | Net cash position 2025 * | 70.24M | EV / Sales 2025 * | 4.81 x |
P/E ratio 2024 * |
-28.4
x | P/E ratio 2025 * |
26.2
x | Employees | 154 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 95.29% |
Latest transcript on Avadel Pharmaceuticals plc
1 day | +1.91% | ||
1 week | -0.74% | ||
Current month | -11.89% | ||
1 month | -7.67% |
Managers | Title | Age | Since |
---|---|---|---|
Gregory Divis
CEO | Chief Executive Officer | 57 | 17-01-02 |
Thomas McHugh
DFI | Director of Finance/CFO | 59 | 19-12-01 |
Scott Macke
COO | Chief Operating Officer | - | 14-08-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Eric Ende
BRD | Director/Board Member | 55 | 18-11-30 |
Gregory Divis
CEO | Chief Executive Officer | 57 | 17-01-02 |
Mark McCamish
BRD | Director/Board Member | 72 | 19-12-04 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-21 | 16 | +1.91% | 528,602 |
24-05-20 | 15.7 | +1.36% | 402,538 |
24-05-17 | 15.49 | -2.82% | 573,405 |
24-05-16 | 15.94 | -0.93% | 606,062 |
24-05-15 | 16.09 | -0.19% | 1,116,873 |
Delayed Quote Nasdaq, May 21, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+11.19% | 1.51B | |
+37.78% | 705B | |
+32.82% | 583B | |
-3.51% | 364B | |
+19.94% | 332B | |
+5.14% | 291B | |
+16.64% | 238B | |
-4.13% | 210B | |
+10.63% | 209B | |
+9.32% | 169B |
- Stock Market
- Equities
- AVDL Stock